Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMR), or connected persons, specifically regarding the vesting of share options.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity compensation events.
- Option Exercise Price: £11.77 per Ordinary share (US $33.42 per ADS).
- Market Price (Feb 17, 2012): £14.14 per Ordinary share.
- Vesting Date: February 17, 2012.
Material Changes
The material event reported is the completion of the three-year vesting period for share options granted in 2009. Consequently, the options became fully exercisable on February 17, 2012. No financial performance changes versus prior periods are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a regulatory disclosure required under Disclosure and Transparency Rule 3.1.4R(1)(c).
Important Facts for Investors
- Option Vesting: Options granted in 2009 vested for specific PDMRs and connected persons.
- Beneficiaries:
- Mr. P Thomson and Mrs. K Thomson: 1,005 ADSs vested.
- Dr. M Slaoui (Executive Director) and Mrs. K Slaoui: 1,100 ADSs vested.
- Transaction Timing: The company and named persons were advised of these transactions on February 20, 2012.
- Financial Impact: The filing does not quantify the total financial impact or number of options held by all employees, only those of connected persons.